TY - JOUR
T1 - New perspectives on respiratory syncytial virus surveillance at the national level
T2 - lessons from the COVID-19 pandemic
AU - Teirlinck, Anne C
AU - Johannesen, Caroline K
AU - Broberg, Eeva K
AU - Penttinen, Pasi
AU - Campbell, Harry
AU - Nair, Harish
AU - Reeves, Rachel
AU - Bøås, Håkon
AU - Brytting, Mia
AU - Cai, Wei
AU - Carnahan, Annasara
AU - Casalegno, Jean-Sebastien
AU - Danis, Kostas
AU - De Gascun, Cillian F
AU - Ellis, Joanna
AU - Emborg, Hanne-dorthe
AU - Gijon, Manuel
AU - Guiomar, Raquel
AU - Hirve, Siddhivinayak
AU - Jirincova, Helena
AU - Nohynek, Hanna
AU - Oliva, Jesus Angel
AU - Osei-Yeboah, Richard
AU - Paget, John
AU - Pakarna, Gatis
AU - Pebody, Richard
AU - Presser, Lance
AU - Rapp, Marie
AU - Reiche, Janine
AU - Rodrigues, Ana Paula
AU - Seppälä, Elina
AU - Socan, Maja
AU - Szymanski, Karol
AU - Trebbien, Ramona
AU - Vecerova, Jaromira
AU - van der Werf, Sylvie
AU - Zambon, Maria
AU - Meijer, Adam
AU - Fischer, Thea K
N1 - Funding Information:
Conflict of interest: The content of the workshop on RSV surveillance was organised by SSI, RIVM and ECDC. This workshop was organised as an element of the Respiratory Syncytial Virus Consortium in Europe (RESCEU). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 116019. This Joint Undertaking receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. This workshop was only attended by publicly funded participants of academic and public health bodies. No industrial partners participated in the meeting or were involved in writing this manuscript. The institutions of the following co-authors are partners in RESCEU: National Institute for Public Health and the Environment, RIVM, the Netherlands (A.C. Teirlinck, A. Meijer, L. Presser); Statens Serum Institute, SSI, Denmark (T.K. Fischer, R. Trebbien, H-D. Emborg and C.K. Johannesen); University of Edinburgh (H. Nair, H. Campbell, R. Osei-Yeboah); PENTA (M. Gijjon). The institutions of the following co-authors are affiliated partners in RESCEU: Norwegian Institute of Public Health (H. Bøås, E. Seppälä); Nivel, the Netherlands ( J. Paget), Finnish Institute for Health and Welfare THL (H. Nohynek). E.K. Broberg and P. Penttinen (both ECDC) are members of the Scientific Advisory Group of RESCEU. H. Nohynek reports grants from GSK, Sanofi-Pasteur and Pfizer (to their institute THL, not their unit), outside the submitted work; and membership of the ESWI Scientific Committee. In addition, H. Nohynek has participated on data safety monitoring boards related to COVID-19 and Pertussis vaccines. J. Paget reports unrestricted research grants from Sanofi Pasteur, WHO, and Foundation for Influenza Epidemiology to Nivel, outside the submitted work. A.P. Rodrigues reports grants from AstraZeneca and Sanofi-Pasteur, and travel support from AstraZeneca, outside the submitted work. H. Nair reports grants from IMI, NIHR, WHO and Pfizer, consulting fees from BMGF, honoraria from AstraZeneca (all to their institute) and participated in DSM boards/advisory boards for Sanofi, ReViral, Novavax and GSK outside the submitted work. H. Campbell reports grants from EU IMI to the University of Edinburgh during the conduct of the study. H. Campbell also reports grants, consulting fees and travel support from WHO, BMGF and Sanofi (all paid via the University of Edinburgh). R.M. Reeves reports employment by IQVIA Real-World Solutions, and honoraria for manuscript writing from Sanofi Pasteur, both outside the submitted work. S. van der Werf reports a grant from Sanofi Pasteur, patents and participation in data safety monitoring boards and advisory boards, all outside the submitted work. C. De Gascun reports lecture honoraria from Sanofi-Aventis Ireland Limited, outside the submitted work. All other authors report no conflicts of interest outside the submitted work.
Publisher Copyright:
Copyright © The authors 2023.
PY - 2023/4/3
Y1 - 2023/4/3
N2 - Learning from the COVID-19 pandemic and considering the effects of this pandemic, we providerecommendations that can guide towards sustainable RSV surveillance with the potential to beintegrated into the broader perspective of respiratory surveillance.
AB - Learning from the COVID-19 pandemic and considering the effects of this pandemic, we providerecommendations that can guide towards sustainable RSV surveillance with the potential to beintegrated into the broader perspective of respiratory surveillance.
U2 - 10.1183/13993003.01569-2022
DO - 10.1183/13993003.01569-2022
M3 - Article
SN - 0903-1936
VL - 61
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 4
M1 - 2201569
ER -